2023-12-007 - CONAN (Controlled-replication ONcolytic AdeNovirus): Generation of a controlled-replication oncolytic adenovirus for cancer treatment
Contacts
LT
Acronim & Gínjol codes
CONAN
2023-12-007
Main technology offer
Generation of a controlled-replication oncolytic adenovirus for cancer treatment. Modify ICOVIR15, an oncolytic adenovirus generated in our laboratory, to enable controlled replication
Ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Social: health and safety
The impact on cancer patients effective therapy would not only reduce hospital days and side effects of currently used drugs, but also improve quality of life and increase survival.
Market Data
Our proposal involves the therapeutic use of mesenchymal cells that serve as carriers for an oncolytic adenovirus designed to selectively target and eliminate tumor cells while preserving healthy tissue (tumor-selective replication viruses). To date, the clinical evaluation program for CELYVIR has completed 4 clinical trials and is currently under evaluation in two more. Despite clinical results have demonstrated some objective antitumor responses, which in certain cases have resulted in complete disease elimination, we have identified the limited delivery of cells and the virus to the tumor as the primary challenge of the therapy. We are presenting an innovative project focusing on developing a technology that improves not only CELYVIR, but any therapy that combines in a cell vehicle and adenoviruses, so that they overcome the limitations described. Our proposal is based on a system that allows us to control at will when we want CELYVIR to start replicating the oncolytic virus. In this way, we will first give CELYVIR time to reach the tumor, and once there, allow the virus to replicate, increasing its concentration in the tumor mass and thus improving the antitumor capacity of therapy.
0
0
0
The transfer strategy that we are developing in this project is based on the application for a European priority patent and extension via PCT, for future licensing to a company specialised in the production and development of viruses for their validation in clinical phases, where our knowledge and experience will be key to their success.
The immunotherapy field urgently requires the creation of advanced oncolytic viruses as part of new Advanced Therapy Medicinal Products (ATMPs). These novel therapeutics should demonstrate both superior efficacy and an excellent safety profile for treating cancer patients. By focusing on developing innovative ATMPs, researchers aim to enhance the potential of oncolytic viruses, offering more effective and safer treatment options in the fight against cancer
Cancer immunotherapy: oncolytic viruses for solid tumors
Funding
150 K to complete preclinical proof of concept
Licensing opportunities or establishing financial collaborations with interested companies Industrial partners for codevelopment and licensing deals
Objective: Development of the pre-clinical proof of concept of our technological product. 1. Generation of a second viral candidate. 2. In vitro candidate comparison tests. 3. In vivo assays of functionality and anti-tumour efficacy of the system. 4. In vivo safety tests of the system. 5. Preclinical and clinical regulatory roadmap for ATMP development 6. PCT extension
Technology Status
We are presenting an innovative project focusing on developing a technology that improves not only CELYVIR, but any therapy that combines in a cell vehicle and adenoviruses, so that they overcome the limitations described. Our proposal is based on a system that allows us to control at will when we want CELYVIR to start replicating the oncolytic virus. In this way, we will first give CELYVIR time to reach the tumor, and once there, allow the virus to replicate, increasing its concentration in the tumor mass and thus improving the antitumor capacity of therapy.
Regulatory barriers for GMP Production
Develop a viral candidate with a high safety and efficacy profile in vivo to codevelop or license our project to a specialized company for the further development of our asset. Finalize the regulatory preclinical phase of our asset and define a roadmap to initiate the first in human clinical trial (glioblastoma and ovarian cancer)
Patent submitted: EP24382337 Priority date 27/03/2024 Positive European Extended Search Report (EESR) 02/10/2024 PCT submitted: PCT/EP2025/058307 Date:26/03/2025
EP24382337 Priority date 27/03/2024
Additional information
This concept stems from the observed limitation in CELYVIR, which employs mesenchymal stem cells (MSCs) as carriers for the oncolytic adenovirus ICOVIR5 (the predecessor of ICOVIR15). The observed limitation is that the amount of virus reaching the tumor is low. Among other factors, this limitation may be due to the infected cells not having enough time to reach the tumor because the virus completes its lytic cycle in about 72-96 hours.